Anticancer therapeutic intervention
AssigneePhyzat Biopharmaceuticals, Lda.
InventorPatricio Soares da Silva
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method of treating cancer using interfering RNA duplexes to mediate gene silencing. The present invention is also directed to interfering RNA duplexes and vectors encoding such interfering RNA duplexes.
Claims9
An siNA (short interfering nucleic acid) molecule that can reduce expression of a LAT1 gene in a cell, wherein said molecule comprises a nucleic acid sequence selected from SEQ ID NO:
- 152, 153, 159, 162 and 184, or a nucleic acid sequence that differs from one of SEQ ID NO:
- 152, 153, 159, 162 and 184 by no more than one nucleotide, or said molecule comprises a nucleic acid sequence that is perfectly complementary to the full length of a sequence selected from SEQ ID NO:
- 152, 153, 159, 162 and 184, or is a variant thereof that differs from the perfectly complementary nucleic acid sequence by no more than 1 nucleotide.
An siNA molecule, where said molecule comprises a sense sequence with a nucleic acid sequence selected from SEQ ID Nos 387 and 389 or a nucleic acid sequence that differs from one of SEQ ID Nos 387 and 389 by no more than one nucleotide, and an antisense sequence with a nucleic acid sequence selected from SEQ ID Nos 388, 390, and 412 or a nucleic acid sequence that differs from one of SEQ ID Nos 388, 390, and 412 by no more than one nucleotide.
Dependencies are inferred from the claim text.